Advanced Heart Failure and Transplant Cardiology · Las Vegas, NV
NPI
1952668220
Since 2012
Specialty
Advanced Heart Failure and Transplant Cardiology
Code 207RA0001X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
10040 Alta Dr Ste 350
Las Vegas, NV, 89145
Phone (702) 360-7600
Groups this clinician bills Medicare through
Medicare paid, 2024
$65K
647 services
Medicare patients, 2024
232
Average age 77
Drug cost, 2024
$13.9M
6,368 prescriptions
Company payments, 2025
$6,003
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Corey J Lum was code 99215 (office e&m - established), 237 times for 94 patients. In total Corey J Lum billed 647 services in 27 codes, and Medicare paid $65K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-04-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 237 | 94 | $132.00 | $31K |
| 93306 Echocardiography (TTE/TEE) | Office | 111 | 106 | $139.01 | $15K |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 31 | 30 | $25.07 | $777 |
| 99233 Hospital E&M - Subsequent | Facility | 30 | 23 | $88.46 | $2,654 |
| 93356 Echocardiography (TTE/TEE) | Office | 29 | 26 | $26.37 | $765 |
| 99205 Office E&M - New | Office | 28 | 28 | $170.28 | $4,768 |
| Q9957 Injection, perflutren lipid microspheres, per ml | Office | 27 | 16 | $31.40 | $848 |
| 99223 Hospital E&M - Initial | Facility | 19 | 18 | $132.74 | $2,522 |
| 99152 Anesthesia | Facility | 14 | 14 | $9.24 | $129 |
| 93000 Electrocardiogram | Office | 12 | 12 | $11.04 | $132 |
By year: 2022 $50K for 500 services; 2023 $61K for 538 services; 2024 $65K for 647 services.
Medicare prescription drug claims, 2024
In 2024, the drug Corey J Lum prescribed most often to Medicare patients was Metoprolol Succinate, with 619 prescriptions and refills. In total Corey J Lum wrote 6,368 Medicare prescriptions that cost $13.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Metoprolol Succinate Generic | 619 | 1,881 | 240 | $8,736 |
| Furosemide Generic | 558 | 1,661 | 279 | $3,254 |
| Spironolactone Generic | 540 | 1,643 | 215 | $3,368 |
| Jardiance Empagliflozin | 491 | 1,256 | 193 | $740K |
| Carvedilol Generic | 454 | 1,368 | 165 | $3,382 |
| Entresto Sacubitril/Valsartan | 345 | 821 | 121 | $464K |
| Vyndamax Tafamidis | 342 | 350 | 49 | $8.4M |
| Atorvastatin Calcium Generic | 336 | 1,026 | 132 | $2,911 |
| Eliquis Apixaban | 314 | 764 | 98 | $438K |
| Torsemide Generic | 195 | 547 | 77 | $5,547 |
| Camzyos Mavacamten | 170 | 172 | 21 | $1.4M |
| Amiodarone Hcl Generic | 156 | 464 | 69 | $2,015 |
| Losartan Potassium Generic | 127 | 368 | 51 | $936 |
| Farxiga Dapagliflozin Propanediol | 116 | 257 | 37 | $144K |
| Opsumit Macitentan | 111 | 111 | 17 | $1.4M |
Brand drugs: - claims; generic drugs: 4,197 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Corey J Lum $6,003 ($6,003 in general payments such as food, travel and fees) from 13 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $2,814.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $2,814 |
| Abbott Laboratories ABT | 21 | $1,833 |
| Abiomed JNJ | 2 | $284 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $256 |
| Medtronic, Inc. MDT | 9 | $192 |
| BridgeBio Pharma, Inc. BBIO | 1 | $149 |
| Merck Sharp & Dohme LLC MRK | 1 | $125 |
| Inspire Medical Systems, Inc. INSP | 1 | $119 |
| Alnylam Pharmaceuticals Inc. ALNY | 1 | $112 |
| Philips North America LLC PHG | 2 | $51.03 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.